[Federal Register Volume 78, Number 143 (Thursday, July 25, 2013)]
[Notices]
[Pages 44954-44955]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-17868]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee (CLIAC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting of the aforementioned
committee:
Times and Dates:
8:30 a.m.-5:00 p.m., August 21, 2013
8:30 a.m.-12:00 p.m., August 22, 2013
Place: CDC, 1600 Clifton Road NE., Tom Harkin Global Communications
Center, Building 19, Room 232, Auditorium B, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services; the Assistant Secretary for Health; the Director, Centers for
Disease Control and Prevention; the Commissioner, Food and Drug
Administration; and the Administrator, Centers for Medicare and
Medicaid Services. The advice and guidance pertain to general issues
related to improvement in clinical laboratory quality and laboratory
[[Page 44955]]
medicine practice and specific questions related to possible revision
of the CLIA standards. Examples include providing guidance on studies
designed to improve safety, effectiveness, efficiency, timeliness,
equity, and patient-centeredness of laboratory services; revisions to
the standards under which clinical laboratories are regulated; the
impact of proposed revisions to the standards on medical and laboratory
practice; and the modification of the standards and provision of non-
regulatory guidelines to accommodate technological advances, such as
new test methods and the electronic transmission of laboratory
information.
Matters To Be Discussed: The agenda will include agency updates
from the CDC, the Centers for Medicare & Medicaid Services (CMS), and
the Food and Drug Administration (FDA). Presentations and discussions
will include improving laboratory quality in diverse settings, to
include sites that perform waived testing as well as laboratories
implementing telehealth initiatives such as digital pathology.
Advancing laboratory interoperability in health information technology
will also be discussed.
Agenda items are subject to change as priorities dictate.
Webcast: The meeting will also be Webcast. Persons interested in
attending the in-person meeting or viewing the Webcast can access
information about doing so at this URL: http://wwwn.cdc.gov/cliac/default.aspx
Online Registration Required: All in-person CLIAC attendees are
required to register for the meeting online at least 5 business days in
advance for U.S. citizens and at least 10 business days in advance for
international registrants. Register at http://wwwn.cdc.gov/cliac/default.aspx by scrolling down and clicking the appropriate link under
``Meeting Registration'' (either U.S. Citizen Registration or Non-U.S.
Citizen Registration) and completing all forms according to the
instructions given. Please complete all the required fields before
submitting your registration and submit no later than August 14, 2013
for U.S. registrants and August 7, 2013 for international registrants.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments whenever possible. Oral Comments: In general, each
individual or group requesting to make an oral presentation will be
limited to a total time of five minutes (unless otherwise indicated).
Speakers must also submit their comments in writing for inclusion in
the meeting's Summary Report. To assure adequate time is scheduled for
public comments, individuals or groups planning to make an oral
presentation should, when possible, notify the contact person below at
least one week prior to the meeting date. Written Comments: For
individuals or groups unable to attend the meeting, CLIAC accepts
written comments until the date of the meeting (unless otherwise
stated). However, it is requested that comments be submitted at least
one week prior to the meeting date so that the comments may be made
available to the Committee for their consideration and public
distribution. Written comments, one hard copy with original signature,
should be provided to the contact person below. Written comments will
be included in the meeting's Summary Report.
Availability of Meeting Materials: To support the green initiatives
of the federal government, the CLIAC meeting materials will be made
available to the Committee and the public in electronic format (PDF) on
the internet instead of by printed copy. Check the CLIAC Web site on
the day of the meeting for materials. Note: If using a mobile device to
access the materials, please verify the device's browser is able to
download the files from the CDC's Web site before the meeting.
Alternatively, the files can be downloaded to a computer and then
emailed to the portable device. An internet connection, power source
and limited hard copies may be available at the meeting location, but
cannot be guaranteed. http://wwwn.cdc.gov/cliac/cliac_meeting_all_documents.aspx
Contact Person for Additional Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch, Division of Laboratory Science
and Standards, Laboratory Science, Policy and Practice Program Office,
Office of Surveillance, Epidemiology and Laboratory Services, CDC, 1600
Clifton Road NE., Mailstop F-11, Atlanta, Georgia 30329-4018; telephone
(404) 498-2741; fax (404) 498-2210; or via email at [email protected].
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2013-17868 Filed 7-24-13; 8:45 am]
BILLING CODE 4163-18-P